Exhaled Breath Condensate Assessment in Stable Non-Cystic Fibrotic Bronchiectasis
China121 participantsStarted 2018-06-25
Plain-language summary
The measurement of markers in the expired breath condensate has proven to be a useful method for assessing and monitoring airway inflammation. The aim of this study is to determine the amounts of pH in the expired breath condensate of patients with bronchiectasis, and the relationship between pH and the severity of bronchiectasis.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Willing to join in and sign the informed consent form.
✓. Age\>18 years, the diagnosis of bronchiectasis need reference to the definition of "non-cystic fibrosis bronchiectasis guideline" published by British Thoracic Society in 2010 or 2012 China bronchiectasis expert consensus, clinical symptoms of cough and expectoration, with or without intermittent hemoptysis, and chest CT showed bronchiectasis there.
✓. All patients were clinically stable and had no evidence of infection or acute infective exacerbation (lower or upper respiratory tract) for at least 4 weeks before the study.
✓. Patients with good compliance: the subject must be willing to follow the test plan requirements in the research center to complete all the assessment of the visit.
✓. All normal subjects had a negative history of allergy (negative skin prick tests to common allergens);
✓. Normal lung function, and normal bronchial reactivity.
✓. No history of any lung disease (except for the history of pneumonia in the past time and small pulmonary nodules).
Exclusion criteria
✕. Patients with a history of other respiratory diseases (cystic fibrosis, allergic bronchopulmonary aspergillosis, asthma, 1-antitrypsin deficiency, pulmonary tuberculosis, COPD, lung cancer, interstitial lung disease)and atopic diseases were excluded；